31.68 USD
↗ 0.63 (2.03%)AT CLOSE (11:59 AM EDT)
NewAmsterdam Pharma Company N.V. Ordinary Shares
NAMSNASDAQ • USD
32.19
↗ 0.51 (1.62%)
POST MARKET (AS OF 04:19 PM EDT)
Post Market
AS OF 04:19 PM EDT
32.19
↗ 0.51 (1.62%)
Market: OPEN
Shares of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) are trading at $32.10. Our models show a "Strong Sell" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Furthermore, NAMS is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Jul 17, 2026.
Open?$30.74
High?$32.09
Low?$30.70
Prev. Close?$31.05
Volume?704.4K
Avg. Volume?1.1M
VWAP?$31.58
Rel. Volume?0.64x
Bid / Ask
Bid?$26.35 × 100
Ask?$38.84 × 100
Spread?$12.49
Midpoint?$32.60
Valuation & Ratios
Market Cap?3.6B
Shares Out?116.9M
Float?62.2M
Float %?53.2%
P/E Ratio?N/A
P/B Ratio?5.46
EPS?-$1.82
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Employees
100
Market Cap
3.6B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2022-11-23
Address
GOOIMEER 2-35
NARRDEN, P7 1411 DC
Phone: 35 206 2971
NARRDEN, P7 1411 DC
Phone: 35 206 2971
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?100
Momentum?50
Short Sent.?54
Piotroski F-Score?1/9Weak
Altman Z-Score?30.78Safe
Confidence?55%Low
Short InterestHigh
Short % of Float?14.61%High
Short Interest?9.1M
Days to Cover?6.9
Free Float62.2M
Avg Daily Volume1.3M
Settlement Date2026-06-30
Financial Health
Current Ratio?9.74Strong
Quick Ratio?9.74Strong
Cash Ratio?6.79Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?5.46FAIR▾
Peers100
S&P34
P/S?160.86HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-14.8CHEAP▾
S&P97
EV/Sales?140.58HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-32.0%WEAK▾
S&P6
ROA?-29.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-142187000
Enterprise Value?$3.2B
Fundamentals ratios updated end of day